Last reviewed · How we verify
NCT06733753
Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules
trial testing ultrasound-guided thermal ablation in Thyroid Nodule in 600 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 9 December 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across China |
Drugs / interventions tested
- ultrasound-guided thermal ablation
Conditions studied
- Thyroid Nodule — all drugs for Thyroid Nodule →
Sponsor
Chinese PLA General Hospital
Who can join
18 and older, any sex, with Thyroid Nodule. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for Bethesda III/IV thyroid nodules
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06733753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ultrasound-guided thermal ablation
Trials testing the same drug.
- NCT06733740 — Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma · recruiting
- NCT06733766 — Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer · recruiting
- NCT06729762 — Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules · recruiting
- NCT06316895 — The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma · recruiting
- NCT06340945 — The Outcomes of Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules · NA · recruiting
Other recruiting trials for Thyroid Nodule
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07488325 — Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytol · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07287176 — Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System · NA · recruiting
- NCT06730321 — Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment · recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06733753 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06733753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing